Multiantigenic subunitary vaccines against tuberculosis in clinical trials: Where do we stand and where do we need to go?

被引：4

作者：

Guapillo, Carolina ^{[1
]}

Hernandez-Pando, Rogelio ^{[1
]}

Alberto Flores-Valdez, Mario ^{[2
]}

机构：

[1] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Patol, Secc Patol Expt, Mexico City, DF, Mexico

[2] Ctr Invest & Asistencia Tecnol & Diseno Estado Ja, Biotecnol Med & Farmaceut, Ave Normalistas 800, Guadalajara 44270, Jalisco, Mexico

来源：

HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2016年 / 12卷 / 05期

关键词：

clinical trials; multiantigenic; tuberculosis; vaccines; MYCOBACTERIUM-TUBERCULOSIS; NEGATIVE ADULTS; IMMUNOGENICITY; MTB72F/AS02; ANTIGENS; HUMANS; SAFETY;

D O I：

10.1080/21645515.2015.1136760

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The idea of presenting this commentary is to bring attention to the current status of clinical tests from several multiantigen vaccine candidates based on proteins produced by means of genetic engineering and molecular biology approaches and to suggest how new emerging technologies (OMICs) and bioinformatics might benefit vaccine development for better control of tuberculosis.

引用

页码：1193 / 1195

页数：3

共 50 条

[41] Pediatric bladder tissue engineering: Where have we been and where do we go next? [J].

Ramakrishnan, Venkat M. ;

Thaker, Hatim ;

Ocampo, Gabriel-Luis ;

Adam, Rosalyn M. ;

Estrada, Carlos R. .

JOURNAL OF PEDIATRIC UROLOGY, 2025, 21 (03) :550-557

[42] High-frequency oscillations - Where we are and where we need to go [J].

Engel, Jerome, Jr. ;

da Silva, Fernando Lopes .

PROGRESS IN NEUROBIOLOGY, 2012, 98 (03) :316-318

[43] Rituximab treatment in lupus nephritis - where do we stand? [J].

Gunnarsson, I. ;

Jonsdottir, T. .

LUPUS, 2013, 22 (04) :381-389

[44] Mechanisms of quinolone action and resistance: where do we stand? [J].

Correia, Susana ;

Poeta, Patricia ;

Hebraud, Michel ;

Capelo, Jose Luis ;

Igrejas, Gilberto .

JOURNAL OF MEDICAL MICROBIOLOGY, 2017, 66 (05) :551-559

[45] Atrial Fibrillation Ablation in Octogenarians: Where Do We Stand? [J].

Stepanyan, Gevorg ;

Gerstenfeld, Edward P. .

CURRENT CARDIOLOGY REPORTS, 2013, 15 (10)

[46] Explanted Vascular and Endovascular Graft Analysis: Where Do We Stand and What Should We Do? [J].

Lejay, Anne ;

Colvard, Benjamin ;

Magnus, Louis ;

Dion, Delphine ;

Georg, Yannick ;

Papillon, Julie ;

Thaveau, Fabien ;

Geny, Bernard ;

Swanstrom, Lee ;

Heim, Frederic ;

Chakfe, Nabil .

EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 2018, 55 (04) :567-576

[47] Platelet component transfusion and alloimmunization: Where do we stand? [J].

Moncharmont, P. .

TRANSFUSION CLINIQUE ET BIOLOGIQUE, 2018, 25 (03) :172-178

[48] Carbohydrate for weight and metabolic control: Where do we stand? [J].

Acheson, Kevin J. .

NUTRITION, 2010, 26 (02) :141-145

[49] Translating tolerogenic therapies to the clinic - where do we stand? [J].

Issa, Fadi ;

Wood, kathryn J. .

FRONTIERS IN IMMUNOLOGY, 2012, 3

[50] Accelerated Partial Breast Irradiation: Where Do We Stand? [J].

Dirbas, Frederick M. .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2009, 7 (02) :215-225

← 1 2 3 4 5 →